Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2−, high-risk early breast cancer: 5-year Chinese population analysis of the pha... by Qingyuan Zhang, Kunwei Shen, Chuan-gui Song, Quchang Ouyang, Zhenzhen Liu, Qiang Liu, Jifeng Feng, Joanne W. Y. Chiu, Jinhai Tang, Zefei Jiang, Ling-Ming Tseng, Xiaojia Wang, Liu Yang, Chenxi Qian, Zhimin Shao

Get full text

Real-world effectiveness of goserelin 10.8-mg compared to goserelin 3.6-mg in premenopausal and perimenopausal Chinese patients with hormone receptor positive breast cancer: a coho... by Yongsheng Wang, Xi Wang, Jiong Wu, Hong Liu, Jiuda Zhao, Jian Huang, Jianxia Liu, Youling Gong, Hao Wang, Huaqing Yang, Guorong Zou, Quchang Ouyang, Guoqin Jiang, Huijuan Liu, Sujie Ni, Binghe Xu, Jinming Yu

Get full text

Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real‐world evidence in metastatic breast cancer by Binliang Liu, Zhe‐Yu Hu, Ning Xie, Liping Liu, Jing Li, Xiaohong Yang, Huawu Xiao, Xuran Zhao, Can Tian, Hui Wu, Jun Lu, Jianxiang Gao, Xuming Hu, Min Cao, Zhengrong Shui, Yu Tang, Quchang Ouyang

Get full text

Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross... by Benlong Yang, Zhengkui Sun, Quchang Ouyang, Zhongsheng Tong, Shu Wang, Hongyuan Li, Zhaofeng Niu, Yiding Chen, Lin-xiaoxi Ma, Haoqi Wang, Mu Tang, Zheyu Hu, Xueqiang Gao, Xu Wang, Fei Xie, Qiao Cheng, Yong Shen, Cuizhi Geng, Haibo Wang, Jiong Wu

Get full text

Efficacy and safety of KN026 and docetaxel for HER2‐positive breast cancer: a phase II clinical trial by Jianli Ma, Jingxuan Wang, Ting Xu, Quchang Ouyang, Xiaojia Wang, Jingfen Wang, Lu Gan, Zhong Ouyang, Daren Lin, Tao Sun, Changping Shan, Herui Yao, Baochun Zhang, Zhengguang Li, Zhixiang Zhuang, Ying Lu, Hongwei Yang, Jian Huang, Xingwang Yang, Hongmei Sun, Qingyuan Zhang

Get full text

Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis by Jiayu Wang, Qingyuan Zhang, Huiping Li, Zhongsheng Tong, Quchang Ouyang, Huihui Li, Yuee Teng, Biyun Wang, Tao Sun, Jingfen Wang, Wei Li, Zhaofeng Niu, Hongsheng Li, Chang Gong, Shu Wang, Xinshuai Wang, Xinhong Wu, Ning Liu, Guohua Yu, Fei Liu, Xianghui Duan, Shuya Wang, Yaping Meng, Li Wang, Binghe Xu

Get full text

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies by Quchang Ouyang, Jordi Rodon, Yan Liang, Xinhong Wu, Qun Li, Lihua Song, Min Yan, Zhongsheng Tong, YunPeng Liu, Zev A. Wainberg, Ying Wang, Cuizhi Geng, Susanna V. Ulahannan, Guohua Yu, Manish R. Sharma, Xiang Wang, Judy S. Wang, Alexander Spira, Weihong Zhao, Rachel E. Sanborn, Ying Cheng, Xian Wang, Gesha Liu, Yaling Li, Junyou Ge, Elliot Chartash, Omobolaji O. Akala, Yongmei Yin

Get full text